IDEXX Laboratories, Inc. vs Nerdwallet Inc — how do they compare? IDEXX Laboratories, Inc. trades at $556.84 (market cap $44.48B), while Nerdwallet Inc trades at $9.15 (market cap $603.70M). The key difference: IDEXX Laboratories, Inc. is far larger — about 73.7× Nerdwallet Inc's market cap. Which is the better fit depends on your goals.
| IDXX | NRDS | |
|---|---|---|
Market Cap | $44.48B | $603.70M |
Sector | Health | Financials |
52-Week High | $766.68 | $15.93 |
52-Week Low | $520.87 | $7.58 |
Enterprise Value | $45.38B | $518.00M |
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
NerdWallet (NRDS) trades at $9.17, down 0.97% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.29 versus $0.25 expected. Revenue grew to $836.6M in 2025 with improving net margins from -1.9% in 2022 to 5.82%. Valuation metrics appear attractive with P/E of 9.96 and P/S of 0.81. Recent news highlights the company's pivot to higher-margin transactions and launch of financial resilience indices.
The stock presents a compelling value opportunity with 39% upside to the $12.75 consensus target. Strong profitability metrics (93% gross margin, 19.47% ROE) and positive cash flow trends support the bullish case. Key risks include search-driven revenue headwinds and competitive pressures in financial guidance markets. Analyst consensus leans bullish with 4 buy ratings versus 1 hold and 1 sell.
Trailing returns across standard periods
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →